ESMO Open

First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies in @ESMO_Open. Most common TRAES: IRRs (n:14; 7 of G3), pyrexia, myalgia, rash. SD as best response in 39.3% of pts. esmoopen.com/article/S2059-…

Compartment-specific immune and tumor markers associated with clinical outcomes in pts with & without sarcomatoid/rhabdoid RCC treated with ipi & nivo in @ESMO_Open. Better outcomes in PD-L1 high. Increased neutrophils infiltration in sarc/rhabd. esmoopen.com/article/S2059-…

Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell RCC: results from a global RWE study in @ESMO_Open. Large retrospective cohort, rechallenge 6 months or more after previous ICI led to improved PFS & OS. esmoopen.com/article/S2059-…

Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study in @ESMO_Open.Improved PFS & DCR with FTD-TPI Bev, including KRAS p.G12C mCRC. esmoopen.com/article/S2059-…

Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma in @ESMO_Open. 1yr & 2yrs OS rate >70% & >50%, pure WD better PFS, potential prognostic role of CDH18 IHC. esmoopen.com/article/S2059-…

Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia in @ESMO_Open. 969 pts, 6 studies: consistent safety profile, some differences between NA/Europe and Asia. esmoopen.com/article/S2059-…

A randomized Ph3 clinical trial of weekly vs tri-weekly cisplatin-based CRT for LA cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study in @ESMO_Open.No survival differences, better tolerability and QoL for tri-weekly administration. esmoopen.com/article/S2059-…

Ph3 trial of infigratinib vs gem/cis in advanced CCA with FGFR2 fusion/rearrangement: results & reflections on early termination of PROOF 301 in @ESMO_Open. 48/300 randomized pts in >3yrs. New frameworks needed to assess therapies in ultra-rare tumors. esmoopen.com/article/S2059-…

TBCRC 035: randomized ph II pharmacodynamic study of standard and reduced-dose palbociclib with ET in HR+ previously treated metastatic BC in @ESMO_Open. Lower dose of palbociclib may reduce severe neutropenia without compromising molecular response. esmoopen.com/article/S2059-…

ctDNA clearance may serve as a promising predictor of treatment response—not only in neoadjuvant chemotherapy, but also in neoadjuvant endocrine therapy. As MRD assays continue to evolve and our therapeutic strategies advance, the potential to refine risk stratification and personalize care in early breast cancer keeps expanding. The development of liquid biopsy–guided decision-making is just getting started. @ESMO_Open esmoopen.com/article/S2059-…

Pleased to share analysis of early endpoints in KEYNOTE585 @myESMO @ESMO_Open. pCR, mPR, and downstaging showed associations with favorable EFS and OS in gastric/GEJ adenocarcinoma treated with perioperative pembro+chemo. Further validation is warranted. sciencedirect.com/science/articl…

👉How do we combine #TKIs with various forms of #radiotherapy in #NSCLC? When should we interrupt or modify their dose? 💡Just out in @ESMO_Open a collaborative effort between @myESMO and @estro with recommendations for #EGFR, #ALK and #BRAF/MEK inhinitors Happy to have contributed to this practical guide for clinicians Link to the article: kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2… #LCSM @IASLC @ASCO @OncoAlert @OncBrothers @oncodaily @MedscapeOnc @VJOncology @Peerview @EGFRResisters @EgfrUk @EGFRmNSCLC @YoungLungCancer @ALKPositiveinc

PFS2 as a surrogate endpoint for OS in breast cancer randomized controlled clinical trials in @ESMO_Open. Context-dependent association, stronger association with higher PFS2 maturity and OS information fraction. esmoopen.com/article/S2059-…

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors in @ESMO_Open. Evidence-based consensus statements providing guidance on the safety of combining RT with EGFR, ALK, or BRAF/MEK inhibitors. esmoopen.com/article/S2059-…

A novel BRCAm classification system reveals differential responses to PARP inhibition and prognostic outcomes in eOC: a multicenter study in @ESMO_Open. New BRCA1m classification system identifies superior PARPi response in DBD/DBD-BRCT region. esmoopen.com/article/S2059-…

ctDNA in neoadjuvant endocrine therapy for early BC in @ESMO_Open. ctDNA detection before & after neoadjuvant endocrine therapy predicts tumor burden & long-term recurrence risk. Tissue-free ctDNA assays may guide surgery & treatment decisions! esmoopen.com/article/S2059-…

Gut microbiome-driven modulation of the tumor immune microenvironment optimizes dual checkpoint blockade in advanced NSCLC in @ESMO_Open. Greater microbiota diversity associated with CD8+TILs & better outcomes with dual ICIs but not chemo+dual ICIs. esmoopen.com/article/S2059-…

Global advances and future directions in lung cancer care: expert consensus and strategic priorities in @ESMO_Open. Important advances but global disparities, limited trial access, & implementation challenges still hinder progress. esmoopen.com/article/S2059-…

Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for irAEs in NSCLC in @ESMO_Open. High steroid peak dose associated with reduced survival, but not cumulative dose/2nd line immunesuppression. esmoopen.com/article/S2059-…

A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers in @ESMO_Open. Beyond “one-size-fits-all” approach to improve precision medicine in SGC in a potentially cost-effective way. esmoopen.com/article/S2059-…